• Completed

NCT01568866: Phase 3 - Carfilzomib and Dex Vs Bortezomib & Dex for Relapsed Myeloma (ENDEAVOR)

Updated: Jun 13

The ENDEAVOR Trial

KD Vs Vd

ENDEAVOR trial

The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.


Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients (ENDEAVOR)


Sponsor

Amgen


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT01568866


Official Title: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

First Posted : April 2, 2012


Click here for details on ClinicalTrials.gov

 

Bortezomib : National Cancer Institute

Bortezomib : MedlinePlus Drug Information


Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

 

Publications:


Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Lancet Oncol. 2016 Jan;17


Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.

Int J Hematol. 2019 Oct


Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

Blood Cancer J. 2016 Jan


Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

Leuk Lymphoma. 2017 Oct


Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Lancet Oncol. 2017 Oct

 

Locations

United States, California

United States, Colorado

United States, Florida

United States, Georgia

United States, Indiana

United States, Maryland

United States, Michigan

United States, Missouri

United States, New Jersey

United States, New York

United States, North Carolina

United States, Ohio

United States, Pennsylvania

United States, South Carolina

United States, Tennessee

United States, Texas

United States, Utah

Canada, Alberta

Canada, British Columbia

Canada, New Brunswick

Canada, Nova Scotia

Canada, Ontario

Canada, Quebec

Australia, New South Wales

Australia, Queensland

Australia, South Australia

Australia, Victoria

Australia, Western Australia

New Zealand

Europe

United Kingdom

Austria

Belgium

Bulgaria

Czechia

France

Germany

Greece

Hungary

Poland

Italy

Romania

Slovakia

Spain

Ukraine

Asia

Japan

Israel

Russian Federation

Korea, Republic of

Singapore

Taiwan

Thailand

South America

Brazil



Posts Archive